Perspective's promising PRRT trial results and solid financial position make CATX stock an attractive long-term investment ...

The team developed a protocol to continuously activate neurons that produce the signaling molecule somatostatin, which helps ...

The company’s key product is P2045, a proprietary somatostatin (SST) peptide optimized for radioisotope binding. Two lead compounds are in clinical trials for lung cancer—therapeutic candidate ...

The Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for paltusotine for the treatment and long-term maintenance of acromegaly in adults.

Subtle activation of a small subset of neurons in one region of the brain can make male mice resilient to, and even reverse, the detrimental effects of chronic stress. The same is true for female mice ...

Medical treatment of the disease is usually with somatostatin analogs. An open, prospective, single-center study by Maiza et al. examined the long term (≤18 years) antihormonal and antitumor ...

Paltusotine was granted Orphan Drug Designation for the treatment of acromegaly by the FDA in July 2020. This designation is provided to drugs defined as being intended for the safe and effective ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced the appointment of. Ms. Kalofonos will lead the company’s commercial strategy and operations for the potential launch of paltusotine, the ...

Its product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly. The firm is also developing other oral nonpeptide somatostatin agonists for ...

Ariceum will use NorthStar’s Ac-225 to radiolabel its proprietary peptide (SS0110) satoreotide, a first-in-class antagonist of the somatostatin receptor 2 (SSTR2). Satoreotide is being developed as a ...